Glycogen Synthase Kinase-3β Inhibition Attenuates the Development of Bleomycin-Induced Lung Injury

Abstract

Glycogen synthase kinase-3 (GSK-3) is an ubiquitous serine-threonine protein kinase that participates in a multitude of cellular processes and has recently been implicated in the pathophysiology of a number of diseases. The aim of this study is to investigate the effects of TDZD-8, a potent and selective GSK-3β inhibitor, on the development of lung injury caused by administration of bleomycin (BLM). Mice subjected to intra-tracheal administration of BLM developed significant lung injury characterized by marked neutrophil infiltration and tissue edema. An increase in immunoreactivity to nitrotyrosine, iNOS, TNF-α and IL-1β was also observed in the lungs of BLM-treated mice. In contrast, administration of BLM-treated mice with TDZD-8 (1 mg/kg daily) significantly reduced (I) the degree of lung injury, (II) the increase in staining (immunohistochemistry) for myeloperoxidase (MPO), nitrotyrosine, iNOS, TNF-α and IL-1β and (III) the degree of apoptosis, as evaluated by Bax and Bcl-2 immunoreactivity and TUNEL staining. Taken together, these results clearly demonstrate treatment with the GSK-3β inhibitor TDZD-8 reduces the development of lung injury and inflammation induced by BLM in mice.

Keywords

bleomycin cytokines Glycogen synthase kinase-3 (GSK-3)inflammation neutrophil infiltration signal transduction

References

Crooke

S.T.

and Bradner

W.T.

. 1976. Bleomycin, a review. J. Med. 7:333.

Krishna

Liu

Shigemitsu

Gao

Raffln

T.A.

and Rosen

G.D.

. 2001. PG490-88, a derivative of triptolide, blocks bleomycin-induced lung fibrosis. Am. J. Pathol. 158:997.

American Thoracic Society. 2000. Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med. 161:646.

Mapel

D.W.

Samet

J.M.

and Coultas

D.B.

. 1996. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present and future. Chest 110:1058.

Douglas

W.W.

Ryu

J.H.

and Bjoraker

J.A.

. 1997. Colchicine versus prednisone as treatment of usual interstitial pneumonia. Mayo Clin. Proc. 72:201.

Raghu

Depaso

W.J.

and Cain

. 1991. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. Am. Rev. Respir. Dis. 144:291.

Johnson

M.A.

Kwan

Snell

N.J.

Nunn

A.J.

Darbyshire

J.H.

and Turner-Warwick

. 1989. Randomised controlled trial comparing prednisolone alone with cyclcophosphamide and low-dose prednisolone in combination in cryptogenic fibrosing alveolitis. Thorax 44:280.

Peters-Golden

Bailie

Marshall

Wilke

Phan

S.H.

Toews

G.B.

and Moore

B.B.

. 2002. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am. J. Respir. Crit. Care Med. 15:229.

Van Wauwe

and Haefner

. 2003. Glycogen synthase kinase-3 as drug target: from wallflower to center of attention. Drug News Perspect 16:557.

10.

Woodgett

J.R.

2001. Judging a protein by more than its name: GSK-3. Sci. STKE 2001:12.

11.

Cross

D.A.

Alessi

D.R.

Cohen

Andjelkovich

and Hemmings

B.A.

. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785.

12.

Ali

Hoeflich

K.P.

and Woodgett

J.R.

. 2001. Glycogen synthase kinase-3: properties, functions and regulation. Chem. Rev. 101:2527.

13.

Hoeflich

K.P.

Luo

Rubie

E.A.

Tsao

M.S.

Jin

and Woodgett

J.R.

. 2000. Requirement for glycogen synthase kinase-3 β in cell survival and NF-κB activation. Nature 406:86.

14.

Buss

Dorrie

Schmitz

M.L.

Frank

Livingstone

Resch

and Kracht

. 2004. Phosphorylation of serine 468 by GSK-3beta negatively regulates basal p65 NF-kappaB activity. J. Biol. Chem. 279:49571.

15.

Takada

Fang

Jamaluddin

M.S.

Boyd

D.D.

and Aggarwal

B.B.

. 2004. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor. J. Biol. Chem. 279:39541.

16.

Dugo

Collin

and Allen

D.A.

. 2005. GSK-3 beta inhibitors attenuate the organ injury/dysfunction caused by endotoxemia in the rat. Crit. Care Med. 33:1903.

17.

Martin

Rehani

Jope

R.S.

and Michalek

S.M.

. 2005. Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat. Immunol. 6:777.

18.

Whittle

B.J.

Varga

Posa

Molnar

Collin

and Thiemermann

. 2006. Reduction of experimental colitis in the rat by inhibitors of glycogen synthase kinase-3β. Brit. J. Pharmacol. 147:575.

19.

Cuzzocrea

Mazzon

and Di Paola

. 2006. Glycogen synthase kinase-3beta inhibition attenuates the degree of arthritis caused by type II collagen in the mouse. Clin. Immunol. 120:57.

20.

Cuzzocrea

Genovese

and Mazzon

. 2006. Glycogen synthase kinase-3 beta inhibition reduces secondary damage in experimental spinal cord trauma. J. Pharmacol. Exp. Then 318:79.

21.

Chandler

D.B.

Hyde

D.M.

and Giri

S.N.

. 1983. Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am. J. Pathol. 112:170.

22.

Ashcroft

Simpson

J.M.

and Timbrell

. 1988. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J. Clin. Pathol. 41:467.

23.

Mullane

K.M.

Kraemer

and Smith

. 1985. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J. Pharmacol. Methods 14:157.

24.

Diaz-Granados

Howe

and McKay

D.M.

. 2000. Dextran sulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am. J. Pathol. 156:2169.

25.

Verma

I.M.

2004. Nuclear factor (NF)-kappaB proteins: therapeutic targets. Ann. Rheum. Dis. 2:57.

26.

Pan

L.H.

Ohtani

Yamauchi

and Nagura

. 1996. Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis. Pathol. Int. 46:91.

27.

Goldstein

R.H.

and Fine

. 1995. Potential therapeutic initiatives for fibrogenic lung diseases. Chest 108:848.

28.

Bowler

R.P.

Nicks

and Warnick

. 2002. Role of extracellular superoxide dismutase in bleomycin-induced pulmonary fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 282:719.

29.

Beckman

J.S.

1996. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 9:836.

30.

Endoh

Maiese

and Wagner

. 1994. Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Res. 651:92.

31.

Chatham

W.W.

Swaim

Frohsin

Jr Heck

L.W.

Miller

E.J.

and Blackburn

W. D.

Jr . 1993. Degradation of human articular cartilage by neutrophils in synovial fluid. Arthritis Rheum. 36:51.

32.

Pap

and Cooper

G.M.

. 1998. Role of Glycogen Synthase Kinase-3 in the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway. J. Biol. Chem. 32:19929.

33.

Bijur

G.N.

De Sarno

and Jope

R.S.

. 2000. Glycogen synthase kinase-3β facilitates staurosporine- and heat shock-induced apoptosis protection by lithium. J. Biol. Chem. 11:7583.

34.

Bournat

J.C.

Brown

A.M.

and Soler

A.P.

. 2000. Wnt-1 dependent activation of the survival factor NF-kB in PC12 cells. J. Neurocsi. Res. 61:21.

35.

van Weeren

P.C.

de Bruyn

K.M.

de Vries-Smits

A.M.

van Lint

and Burgering

B.M.

. 1998. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J. Biol. Chem. 273:13150.